- Home
- Companies
- Affimed GmbH
- Products
- Model AFM24 - Innate Cell Engager ...
Model AFM24 - Innate Cell Engager Molecule
AFM24, an EGFR-directed ICE® (innate cell engager) molecule, represents a distinctive mechanism that engages innate immune cells by recruiting NK cells and macrophages to the site of the tumor for effective and efficient tumor-cell killing. Potential to treat various solid tumor types with a more acceptable safety profile while remaining immune to the challenge of resistance.
The differentiated MOA does not rely on the EGFR signaling pathway for tumor killing but instead uses EGFR as a docking site only.8 Unlike existing therapies, AFM24 can be used in all EGFR-expressing tumors, including tumors that have become resistant to signaling inhibition.8 AFM24 induces ADCC in KRAS/BRAF-mutated cell lines to a comparable extent as in nonmutated cell lines, which indicatively proves the hypothesis that the novel mechanism does not rely on EGFR signaling.8 The strong binding affinity and ability to target with low antigenic expression differentiates AFM24 from other treatments.
Broad applicability expands horizons for those we can help
Preclinical data of AFM24 indicate promising efficacy across a wide variety of solid tumor types, including, but not limited to lung, colon, renal, and gastric cancers.8 Clinical data are currently being generated, and if successful, AFM24 could address a significant patient population underserved by current therapies. Emerging clinical data of AFM13 demonstrate impressive efficacy across a number of lymphoma types, including T-cell lymphoma and Hodgkin lymphoma.5,7
We are awaiting highly anticipated results in several EGFR-expressing tumors (eg, lung, RCC, CRC), T-cell lymphoma, Hodgkin lymphoma, and additional CD30-positive lymphomas.